40 patents
Page 2 of 2
Utility
Methods and Systems for Somatic Mutations and Uses Thereof
26 Aug 21
This invention provides methods and compositions for detecting somatic mutations in cancer cells.
Andrey ZHARKIKH, Kirsten TIMMS, Michael PERRY, Alexander GUTIN
Filed: 6 May 21
Utility
Genes and gene signatures for diagnosis and treatment of melanoma
1 Jun 21
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 12 Mar 14
Utility
Gene signatures for cancer prognosis
23 Mar 21
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia E. Reid
Filed: 26 Feb 15
Utility
Gene Signatures for Cancer Prognosis
11 Mar 21
Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Filed: 12 Nov 20
Utility
Gene signatures for cancer prognosis
28 Dec 20
Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Filed: 14 May 15
Utility
Methods and Materials for Assessing Loss of Heterozygosity
23 Dec 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 3 Sep 20
Utility
Method for treating cancer
30 Nov 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 18 Sep 19
Utility
Method of Using Biomarkers and Clinical Variables for Predicting Chemotherapy Benefit
9 Sep 20
Provided herein are methods for predicting chemotherapy benefit.
Alexander GUTIN, Julia REID, Ralf KRONENWETT, Marsel SCHEER
Filed: 3 Mar 20
Utility
Genes and Gene Signatures for Diagnosis and Treatment of Melanoma
12 Aug 20
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan WARF, Benjamin ROA, Alexander GUTIN, Darl FLAKE
Filed: 9 Feb 20
Utility
Adjusted Multi-biomarker Disease Activity Score for Inflammatory Disease Assessment
5 Aug 20
Provided herein are methods for assessing response to inflammatory disease therapy.
Ching Chang HWANG, David CHERNOFF, Alexander GUTIN, Darl FLAKE, Jerry LANCHBURY, Paul Scott EASTMAN, Eric SASSO
Filed: 29 Jul 18
Utility
Methods and Materials for Assessing Allelic Imbalance
29 Jul 20
Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 10 Mar 20
Utility
Methods and Materials for Assessing Loss of Heterozygosity
17 Jun 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 23 Feb 20
Utility
Methods and materials for assessing allelic imbalance
20 Apr 20
Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 22 Jan 17
Utility
Methods and materials for assessing loss of heterozygosity
6 Apr 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 23 Jun 16
Utility
Genes and gene signatures for diagnosis and treatment of melanoma
6 Apr 20
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 21 Dec 16
Utility
Methods and Materials for Assessing Loss of Heterozygosity
18 Mar 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 20 Nov 19
Utility
Cancer Biomarkers
19 Feb 20
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Steven STONE, Alexander GUTIN, Susanne WAGNER, Julia REID
Filed: 24 Oct 19
Utility
Methods and Materials for Assessing Loss of Heterozygosity
8 Jan 20
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 18 Sep 19
Utility
Cancer Biomarkers
30 Dec 19
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Filed: 23 Jan 19
Utility
Cancer biomarkers
9 Dec 19
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Filed: 12 Mar 18